268 related articles for article (PubMed ID: 32593677)
21. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
22. Proton Pump Inhibitor Use, H
Paik JM; Rosen HN; Gordon CM; Curhan GC
Calcif Tissue Int; 2018 Oct; 103(4):380-387. PubMed ID: 29754277
[TBL] [Abstract][Full Text] [Related]
23. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
[TBL] [Abstract][Full Text] [Related]
24. Proton Pump Inhibitors, But Not H2-receptor Antagonists, Are Associated With Incident Fractures Among Kidney Transplant Recipients.
Lyu B; Jorgenson MR; Hansen KE; Djamali A; Astor BC
Transplantation; 2020 Dec; 104(12):2609-2615. PubMed ID: 32058466
[TBL] [Abstract][Full Text] [Related]
25. Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study.
Brown JP; Tazare JR; Williamson E; Mansfield KE; Evans SJ; Tomlinson LA; Bhaskaran K; Smeeth L; Wing K; Douglas IJ
Br J Clin Pharmacol; 2021 Aug; 87(8):3150-3161. PubMed ID: 33393677
[TBL] [Abstract][Full Text] [Related]
26. Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study.
Min YW; Lee YC; Kim K; Ryu S; Hong KS; Jeon HH; Kim YS; Park JH; Son HJ; Rhee PL
Korean J Intern Med; 2020 Sep; 35(5):1084-1093. PubMed ID: 31671930
[TBL] [Abstract][Full Text] [Related]
27. The association of melatonin use and hip fracture: a matched cohort study.
Yang T; Wu J; Ding X; Zhou B; Xiong Y
Osteoporos Int; 2023 Jun; 34(6):1127-1135. PubMed ID: 37036474
[TBL] [Abstract][Full Text] [Related]
28. Clinical Use of Acid Suppressants and Risk of Dementia in the Elderly: A Pharmaco-Epidemiological Cohort Study.
Chen LY; Lin HJ; Wu WT; Chen YC; Chen CL; Kao J; You SL; Chou YC; Sun CA
Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33182362
[TBL] [Abstract][Full Text] [Related]
29. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.
Tran KT; McMenamin ÚC; Hicks B; Murchie P; Thrift AP; Coleman HG; Iversen L; Johnston BT; Lee AJ; Cardwell CR
Aliment Pharmacol Ther; 2018 Jul; 48(1):55-64. PubMed ID: 29741272
[TBL] [Abstract][Full Text] [Related]
30. Proton pump inhibitors and myocardial infarction: an application of active comparators in a self-controlled case series.
Chui CSL; Cheung KS; Brown JP; Douglas IJ; Wong ICK; Chan EW; Wong AYS
Int J Epidemiol; 2023 Jun; 52(3):899-907. PubMed ID: 36259933
[TBL] [Abstract][Full Text] [Related]
31. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
Yu EW; Bauer SR; Bain PA; Bauer DC
Am J Med; 2011 Jun; 124(6):519-26. PubMed ID: 21605729
[TBL] [Abstract][Full Text] [Related]
32. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
Kaye JA; Jick H
Pharmacotherapy; 2008 Aug; 28(8):951-9. PubMed ID: 18657011
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
34. Proton pump inhibitors and risk of colorectal cancer.
Abrahami D; McDonald EG; Schnitzer ME; Barkun AN; Suissa S; Azoulay L
Gut; 2022 Jan; 71(1):111-118. PubMed ID: 34210775
[TBL] [Abstract][Full Text] [Related]
35. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study.
Ruigómez A; Kool-Houweling LMA; García Rodríguez LA; Penning-van Beest FJA; Herings RMC
Curr Med Res Opin; 2017 Dec; 33(12):2251-2259. PubMed ID: 28562108
[TBL] [Abstract][Full Text] [Related]
37. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
Ngwenya S; Simin J; Brusselaers N
Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
[TBL] [Abstract][Full Text] [Related]
38. Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study.
Miyano S; Michihata N; Sada KE; Uda K; Matsui H; Fushimi K; Nangaku M; Yasunaga H
Rheumatology (Oxford); 2021 Apr; 60(4):1717-1723. PubMed ID: 33067623
[TBL] [Abstract][Full Text] [Related]
39. Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research.
Secrest MH; Platt RW; Dormuth CR; Chateau D; Targownik L; Nie R; Doyle CM; Dell'Aniello S; Filion KB
Pharmacoepidemiol Drug Saf; 2020 Jan; 29 Suppl 1():26-34. PubMed ID: 30628152
[TBL] [Abstract][Full Text] [Related]
40. Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study.
Liew JW; Peloquin C; Tedeschi SK; Felson DT; Zhang Y; Choi HK; Terkeltaub R; Neogi T
Arthritis Care Res (Hoboken); 2022 Dec; 74(12):2059-2065. PubMed ID: 35245410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
